A Phase 2, Open-label, Randomized Study to Evaluate Prophylactic Interventions on Talquetamab-related Oral Toxicity

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506260-14-00

Acronym

64407564MMY2006

Enrollment

Registered

2024-07-22

Start date

2025-05-13

Completion date

Unknown

Last updated

2025-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

multiple myeloma

Brief summary

As determined by the total WETT testing score: - Rate of occurrence of taste dysfunction dysgeusia - Rate of occurrence of severe dysgeusia - Time to the first onset of severe dysgeusia - Rate of resolution/improvement of dysgeusia at the end of months 3 and 6

Interventions

DRUGClonazepam Orally Disintegrating Tablets

DRUGUSP

DRUGJNJ-64407564

DRUGPregabalin-ratiopharm® 25 mg Hartkapseln

DRUGPregabalin-ratiopharm® 50 mg Hartkapseln

DRUGDEXAMETHASONE ELIXIR

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
As determined by the total WETT testing score: - Rate of occurrence of taste dysfunction dysgeusia - Rate of occurrence of severe dysgeusia - Time to the first onset of severe dysgeusia - Rate of resolution/improvement of dysgeusia at the end of months 3 and 6	—

Countries

Netherlands, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026